# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123245
Filing Date
2024-11-07
Accepted
2024-11-07 16:01:41
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | vor-20240930.htm iXBRL | 10-Q | 1509778
2 | EX-10.1 | vor-ex10_1.htm | EX-10.1 | 44100
3 | EX-31.1 | vor-ex31_1.htm | EX-31.1 | 15955
4 | EX-31.2 | vor-ex31_2.htm | EX-31.2 | 15947
5 | EX-32.1 | vor-ex32_1.htm | EX-32.1 | 15054
| Complete submission text file | 0000950170-24-123245.txt |  | 6089244

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | vor-20240930.xsd | EX-101.SCH | 816788
61 | EXTRACTED XBRL INSTANCE DOCUMENT | vor-20240930_htm.xml | XML | 1057839

Mailing Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140
Business Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140 617-655-6580
Vor Biopharma Inc. (Filer) CIK: 0001817229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39979 | Film No.: 241435390
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)